Overview

This trial is active, not recruiting.

Conditions physical activity, elderly
Treatment web mediated step intervention
Phase phase 2
Sponsor University of Wisconsin, Milwaukee
Collaborator National Institute on Aging (NIA)
Start date August 2009
End date December 2015
Trial size 160 participants
Trial identifier NCT01158638, K01AG025962, StepCount

Summary

Individually tailored, mediated pedometer feedback will provide an effective method to promote physical activity adoption in the elderly

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Intervention model single group assignment
Masking single blind (outcomes assessor)
Primary purpose prevention
Arm
(No Intervention)
Usual Care
(Active Comparator)
Each participant randomized to this study arm will receive a pedometer and a generic recommendation to accumulate 10,000 Steps per Day.
web mediated step intervention
The testing of a web mediated step intervention designed to set weekly step targets, and channel participants through a series of motivational screens depending on compliance or non-compliance with set step goals.
(Experimental)
Participants randomized to this study arm receive an introduction to the study website. Each person utilizes the website to track their daily physical activity steps. Goals are given on a weekly basis to increase steps by 10% per day per week over baseline values. The website channels each participant through a series of motivational messages designed to increase compliance with recommended physical activity targets
web mediated step intervention
The testing of a web mediated step intervention designed to set weekly step targets, and channel participants through a series of motivational screens depending on compliance or non-compliance with set step goals.

Primary Outcomes

Measure
Objectively assessed steps per day
time frame: 12 weeks

Eligibility Criteria

Male or female participants from 50 years up to 85 years old.

Inclusion Criteria: 1. Male or female individuals living in the community. 2. Aged between 50 and 85 years, at screening. 3. Sufficient physical function not to have limitations to participate in physical activity demonstrated by: - Habitual gait speed ≥ 1.5 mph, AND - No use of a cane or walker, AND - Able to walk ≥ 50 feet unaided 4. Sufficient cognitive function, as demonstrated by responses to the mini-mental state examination(>23 score). 5. Be able to read and write in English 6. Sedentary behavior, demonstrated by no regular activity / exercise for previous 6 months and/or a Stage of Change 2 and 3 Exclusion Criteria: 1. Presence of a rapidly progressive or terminal illness condition that is expected to result in significant functional decline during the course of the proposed studies. 2. Significant uncontrolled cardiovascular disease and conditions, e.g. unstable or new onset angina, unrepaired aortic aneurysms, critical aortic stenosis or CAD without bypass, persistent moderate to severe uncontrolled hypertension. 3. Significant uncontrolled metabolic disease, e.g. hemoglobin A1c levels greater than 8.0 and/or glucose levels greater than 300 mg/dL. 4. Fracture of lower extremity within three months. 5. Amputation other than toes. 6. Current history of severe arthritis or orthopedic condition precluding physical activity. 7. Participation in any regular structured exercise (resistance training, Tai Chi, high intensity walking, jogging, cycling, stair climbing, stepping, within the previous 6 months. 8. Individuals that start a new medication that can impact health variables examined during study period (e.g., beta blockers, glucose or cholesterol altering medications), or individuals who alter medication dose that can impact health variables examined within study period.

Additional Information

Official title Utilizing Tailored Step-Count Feedback to Enhance Physical Activity in the Elderly
Principal investigator Scott J Strath, PhD
Trial information was received from ClinicalTrials.gov and was last updated in May 2015.
Information provided to ClinicalTrials.gov by University of Wisconsin, Milwaukee.